FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies

Area of Science:

• Molecular Biology
• Genetics
• Dermatology
• Oncology

Background:

• Fibroblast growth factor receptor (FGFR)2 is a key regulator influenced by FGFs, proteoglycans, isoforms, inhibitors, and microRNAs.
• FGFR2 signaling interacts with critical pathways like hedgehog and bone morphogenetic protein.
• FGFR2 mutations are implicated in congenital skeletal disorders with skin manifestations.

Purpose of the Study:

• To explore the diverse roles of Fibroblast growth factor receptor (FGFR)2 in human health and disease.
• To investigate the consequences of both gain-of-function and loss-of-function mutations in FGFR2.
• To understand FGFR2's involvement in various pathologies, including cancer and developmental disorders.

Main Methods:

• Review of literature on FGFR2 mutations and their associated phenotypes.
• Analysis of studies involving FGFR2 signaling pathways in cancer models.
• Examination of experimental models for FGFR2 loss-of-function in skin development.

Main Results:

• Gain-of-function FGFR2 mutations are found in breast, gastric, and endometrial cancers, with targeted inhibitors showing therapeutic potential.
• Loss-of-function FGFR2 mutations are associated with melanoma.
• Conditional knockout of Fgfr2b in rodents results in skin pathologies and promotes squamous-cell carcinoma.

Conclusions:

• Dysregulation of FGFR2 leads to a wide range of bone and skin diseases.
• FGFR2 plays a critical role in preventing various cancers, and its mutations contribute to tumorigenesis.
• Understanding FGFR2's complex role is crucial for developing treatments for associated disorders.